Despite great breakthrough of targeted therapies (e.g., BRAF inhibitors and MEK inhibitors) have revolutionized the treatment strategies for metastatic melanoma, durable clinical responses remain elusive [10]. The gene discussed is MAP2K7; the disease is metastatic melanoma.